My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 574

    1.

    Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials.

    Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA.

    Health Qual Life Outcomes. 2003 Oct 8;1:53.PMID: 14613569 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.

    Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr.

    J Drugs Dermatol. 2004 Jan-Feb;3(1):27-38.PMID: 14964744 [PubMed - indexed for MEDLINE]Related articles

    3.

    Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].

    Ortonne JP, Shear N, Shumack S, Henninger E; CLEAR Multinational Study Group.

    BMC Dermatol. 2005 Dec 16;5:13.PMID: 16359548 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.

    Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA.

    Health Qual Life Outcomes. 2006 Sep 27;4:71.PMID: 17005043 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

    Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A; Efalizumab Study Group.

    JAMA. 2003 Dec 17;290(23):3073-80. Erratum in: JAMA. 2004 Mar 3;291(9):1070. PMID: 14679270 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.

    Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W.

    Arch Dermatol. 2005 Jan;141(1):31-8.PMID: 15655139 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

    Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A.

    Br J Dermatol. 2005 Dec;153(6):1192-9.PMID: 16307657 [PubMed - indexed for MEDLINE]Related articles

    8.

    Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.

    Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.

    J Dermatolog Treat. 2007;18(1):25-31.PMID: 17365264 [PubMed - indexed for MEDLINE]Related articles

    9.

    Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

    Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.

    J Dermatolog Treat. 2007;18(6):341-50.PMID: 18058494 [PubMed - indexed for MEDLINE]Related articles

    10.

    Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

    Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

    Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.PMID: 17083854 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

    Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.

    Dermatology. 2008;216(3):260-70. Epub 2008 Jan 11.PMID: 18187944 [PubMed - indexed for MEDLINE]Related articles

    12.

    Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

    Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A.

    Br J Dermatol. 2008 Mar;158(3):549-57. Epub 2007 Nov 28.PMID: 18047521 [PubMed - indexed for MEDLINE]Related articles

    13.

    Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials.

    McKenna SP, Cook SA, Whalley D, Doward LC, Richards HL, Griffiths CE, Van Assche D.

    Br J Dermatol. 2003 Aug;149(2):323-31.PMID: 12932239 [PubMed - indexed for MEDLINE]Related articles

    14.

    Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial.

    Ellis CN, Mordin MM, Adler EY; Randomized, placebo-controlled phase II trial.

    Am J Clin Dermatol. 2003;4(2):131-9.PMID: 12553852 [PubMed - indexed for MEDLINE]Related articles

    15.

    Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.

    Br J Dermatol. 2005 May;152(5):954-60.PMID: 15888152 [PubMed - indexed for MEDLINE]Related articles

    16.

    Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.

    Salim A, Tan E, Ilchyshyn A, Berth-Jones J.

    Br J Dermatol. 2006 Jun;154(6):1169-74.PMID: 16704650 [PubMed - indexed for MEDLINE]Related articles

    17.

    Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.

    Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, Mayes MD, Collier DH, Medsger TA Jr, Seibold JR; Relaxin Study Group; Scleroderma Clinical Trials Consortium.

    J Rheumatol. 2005 May;32(5):832-40.PMID: 15868618 [PubMed - indexed for MEDLINE]Related articles

    18.

    The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population.

    Abetz L, Arbuckle R, Allen RP, Mavraki E, Kirsch J.

    Health Qual Life Outcomes. 2005 Dec 5;3:79.PMID: 16329756 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

    Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE.

    Br J Dermatol. 2006 Jun;154(6):1161-8.PMID: 16704649 [PubMed - indexed for MEDLINE]Related articles

    20.

    Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group.

    Badia X, Mascaró JM, Lozano R.

    Br J Dermatol. 1999 Oct;141(4):698-702.PMID: 10583119 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    You are here: NCBI > Literature > PubMed
    Write to the Help Desk